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Abstract 
 
Introduction: Pneumothorax occurs more frequently in the neonatal period than in any other 
period of life and is associated with increased mortality and morbidity. Several risk factors for 
pneumothorax, including respiratory pathology, invasive and non-invasive respiratory support, 
and predictors of mortality have been described. 
Objective: To evaluate the prevalence, to assess risk factors and to describe the clinical 
characteristics, management and outcome of newborn infants with pneumothorax as well as 
identify predictors of mortality in these newborns. 
Methods: This retrospective case-control study included all newborns hospitalized in the NICU 
of Centro Hospitalar São João, Porto, Portugal, between 2003 and 2014, with the diagnosis of 
pneumothorax. A control group was selected among the newborns without pneumothoraces. 
The collected data included: demographics and perinatal data, pneumothorax characteristics, 
classification, treatment and clinical outcomes. 
Results: Our study included 240 neonates (80 with pneumothoraces and 160 controls), of whom 
145 were male (60.4 %). Median gestational age was 37 (24-40) weeks and median birthweight, 
2612.5 (360-4324) grams. The prevalence in our NICU was 1.5 %. Pneumothorax was 
significantly associated with RDS (p=0.010) and TTN (p<0.001). Invasive mechanical 
ventilation (p=0.016) and FiO2>0.4 (p=0.003), were independent risk factors for the -
development of pneumothoraces. The mortality rate was 13.8%. Hypotension, mechanical 
ventilation and thoracentesis followed by a chest tube insertion were found to be predictors of 
mortality in newborns having pneumothoraces, but pneumothorax was not. 
Conclusion: Pneumothorax is relatively frequent in the neonatal intensive care unit. Its risk 
factors and predictors of mortality should be known in order to prevent and treat this critical 
situation. Pneumothorax itself was not a predictor of mortality, probably due to the adequate 
and prompt management used in the NICU. 
 
Keywords: Pneumothorax, newborn, risk factors, mechanical ventilation, neonatal intensive 
care, mortality. 
 
 
 
 
 
 
 Introduction 
 
Pneumothorax occurs more frequently in the neonatal period than in any other period of 
life and is associated with increased mortality and morbidity. It begins with the rupture of an 
over-distended alveoli. The air escapes along the perivascular connective tissue sheath into the 
pleural space, causing pneumothorax and less commonly pneumomediastinum, 
pneumopericardium, subcutaneous emphysema, and pneumoperitoneum, altogether known as 
air leak syndromes. [1,2] 
Pneumothorax is a relatively frequent critical situation in the neonatal intensive care 
unit. Symptomatic pneumothorax occurs in about 0.05% to 0.1% of all live births and in very 
low birthweight infants this rate can achieve 3.8 % to 9%. [3,4] 
 Several risk factors for pneumothorax have been described and include immaturity, 
respiratory distress syndrome (RDS), invasive and non-invasive respiratory support, 
chorioamnionitis, among others. For moderate-late preterm infants risk factors also include 
higher birth weight, male gender, and rupture of membranes longer than 24 hours. [5]  
 Common clinical manifestations of pneumothorax are tachypnea, flaring, hypoxemia 
and hypercapnea. In some cases, there is a mediastinal shift that compromises the 
cardiovascular system and carries a significant risk of an impaired outcome and death. Tension 
pneumothorax causes a rise in intrapleural pressure and subsequent lung collapse, as well as 
impaired venous return, systemic hypotension and cardiac arrest. It is, therefore, essential to 
recognize these risk infants in order to prevent and treat properly this critical situation. [1,4] 
The diagnosis of pneumothorax relies on clinical judgment, transillumination and chest 
radiogram. [6] 
The treatment of neonatal pneumothorax is not fully defined. Three approaches are the 
common practice in NICUs. The expectant approach for small and asymptomatic 
pneumothorax, and active intervention to a significant one, such as needle (14–16 G) aspiration 
and thoracic drainage.[7,8] Needle aspiration is an option in cases of mild to moderate 
pneumothorax when the infant is hemodynamically stable. In hypertensive pneumothoraces the 
common therapeutic approach is chest tube placement. [1] 
The aim of this study was to evaluate the prevalence, to identify risk factors and to 
describe the clinical characteristics, management and outcome of newborn infants with 
pneumothorax as well as to identify the predictor factors of mortality in these newborns. 
 
Material and methods 
 
This retrospective case control study included all newborns hospitalized in the NICU (a 
level III unit with 17 beds and 450 admissions per year and) of Centro Hospitalar São João, 
Porto, between 1st january 2003 and 31st december  2014, with the diagnosis of pneumothorax.  
All the data were collected from the hospital electronic clinical database and medical 
records of the patients. A control group was selected among the newborns without 
pneumothoraces admitted to the NICU in the same years, gender, gestational age (more or less 2 
weeks) and birthweight (more or less 500 g). These data includes: information regarding 
pregnancy and delivery (gestational age, multiple births, type of deliver), gender, birth weight, 
Apgar score at 1 and 5 minutes, the need of resuscitation, antenatal corticotherapy, need for 
surfactant, oxygen therapy, nasal continuous positive airway pressure (NCPAP), conventional 
mechanical ventilation (CMV) and high frequency oscillation ventilation (HFOV) use . 
Pneumothorax characteristics were also obtained (day of life and the duration of the 
pneumothorax) and classified as spontaneous (primary or secondary), iatrogenic (positive 
airway pressure or surgery), hypertensive and persistent. Data about treatment, neonatal 
morbidity and mortality were also collected. Pneumothoraces were diagnosed by chest 
radiography and the type of pneumothorax was assessed according to clinical setting and 
medical history. [1] 
Gestational age was assessed by post-menstrual age, ultrasound examination or the New 
Ballard Score (in the absence of obstetrical indexes). [9, 10] Small for gestational age was 
defined as a birth weight below the 3rd centile of Fenton`s growth charts. [11] Our NICU has a 
protocol for positive pressure ventilation that includes different ventilatory strategies according 
to different lung diseases and favors the use of permissive hypercapnea. For the very low birth 
weight infants NCPAP just after birth is the preferable mode of ventilation. [12] NCPAP is done 
using Infant Flow (Pulmocor, USA), for invasive mechanical ventilation we use Babylog 
(Drager, Germany). HFOV is performed as rescue ventilation (Sensor Medics®, USA). 
Sepsis was considered in the presence of a positive blood culture, combined with 
clinical and laboratory parameters. [13] Intraventricular hemorrhage (IHV) was defined 
according to Papile [14] and Volpe [15] (before and after 2010, respectively), intraventricular 
bleeding with ventricular dilatation is classified as IHV 3 and with parenchymal involvement as 
IHV 4. Retinopathy of prematurity (ROP) was diagnosed and classified according to the 
International Classification of Retinopathy of Prematurity revised. [16] Patent ductus arteriosus 
(PDA) was diagnosed according to SIBEN consensus. [17] Necrotizing enterocolitis (NEC) was 
defined by clinical findings and radiological features, according to the modified Bell criteria. 
[18] Cystic periventricular leukomalacia (PVL) was diagnosed by ultrasound. [19]  
Respiratory distress syndrome was defined based on the European guidelines [20] and 
bronchopulmonary dysplasia (BPD) according to the NIH Consensus definition. [21] Transient 
tachypnea of the newborn (TTN) was diagnosed according to the criteria of Machado and Fiori. 
[22] Pneumonia was diagnosed based on combination of clinical, radiological and laboratory 
parameters. [23] Meconium aspiration syndrome (MAS) was characterized based on Shahed A. 
Criteria. [24] Pulmonary hypoplasia (PH) was defined according on clinical, radiologic, and 
pathologic criteria. [25] 
Hypotension was defined according Cayabyab et al. [26] 
The statistical analysis was performed using SPSS for Windows, version 23. 
Categorical variables were evaluated by absolute and relative frequencies and continuous 
variables were characterized by median (minimum-maximum). All variables were compared 
between neonates with (cases) or without (controls) pneumothorax. Chi-Squared or Fisher’s 
exact test were used to compare categorical variables and Mann Whitney-U test (non-parametric 
test) to compare continuous variables. Risk factors for pneumothorax were evaluated by a 
multivariate analysis by logistic regression. Statistically significance was considered for a p 
value less than 0.05. 
 
Results 
Our study included 240 neonates (80 with pneumothoraces and 160 controls), of whom 
145 were males (60.4 %). Their median gestational age was 37 (24-40) weeks and the median 
birthweight was 2612.5 (360-4324) grams.  The prevalence in our NICU was 1.5 %.  .The 
analysis of demographic and perinatal data of both groups showed statistically significant 
differences in Apgar score at 5th minute (p = 0.002) and in resuscitation at birth (p < 0.001), 
Table 1.   
Table 2 describes the characterization and treatment of pneumothoraces. They were 
spontaneous (primary or secondary to lung disease) in 46 (57.5%) neonates and iatrogenic in 34 
(42.5%). Fifty seven (71.3%) were hypertensive and 2 (2.5%) persistent.  We observed 37 
(46.3%) pneumothoraces in the right lung, 35 (43.8%) in the left and 8 (10%) were bilateral. 
Oxygen therapy was done in 68 (85%) neonates, NCPAP in 15 (18.8%) and IMV in 60 (75%) 
newborns. Thoracentesis was performed in 10 (12.5%) pneumothoraces, but 7 of them also had 
to be drained. To treat the pneumothoraces, 57 (71.3%) neonates needed drains and 3 (3.8%) 
thoracentesis.   
In Table 3 we present the clinical and management data in cases and controls. There 
were statistically significant differences between both groups concerning respiratory pathology 
(pneumonia, MAS, RDS, pulmonary hypoplasia, transient tachypnea of the newborn). IVH ≥3 
grade, PDA, cystic PVL and hypotension were also more frequent in newborns having 
pneumothorax. Use of oxygen therapy (p<0.001), NCPAP (p<0.001) and mechanical ventilation 
(p<0.001) also revealed a significant increase in pneumothorax cases. Statistical significance 
between the two groups was also found for FiO2>0.4 (p < 0.001). The association with 
pneumothorax was found for major congenital malformations: congenital cardiopathy (CHD) 
and diaphragmatic hernia. The average of days of hospitalization was 9.5 in pneumothorax 
group and 4 in controls (p<0.001). The prevalence of death was 24 (30%) in cases and 9 (5.6%) 
in controls (p < 0.001). 
The two respiratory pathologies, RDS (OR 3.512, 95% CI 1.353-9.118, p=0.010) and 
TTN (OR 8.677, 95% CI 2.752-27.354, p<0.001) were significantly associated with 
pneumothorax. Mechanical ventilation was also significantly associated with pneumothorax 
(OR 3.824, 95% CI 1.285-11.376, p<0.016), as was FiO2>0.4 (OR 5.614, 95%CI 1.828-17.238, 
p=0.003), Table 4. Pneumothorax was not identified as a predictor of death OR 1.284, 95% CI 
0.409-4.032, p=0.669). Hypotension, thoracentesis and mechanical ventilation were found to be 
predictors of death in newborns with pneumothoraces, Table 5. 
 
Discussion 
  
 In this study we aimed to compare clinical characteristics between neonates with and 
without pneumothoraces and to identify risk factors of pneumothoraces and predictors of death 
in these patients. 
As expected, there were no significant differences between cases and controls, for 
gender, gestational age and birth weight. Statistically significant differences in Apgar score at 
5th minute occurred due to the need of resuscitation at birth, which was found to be a risk factor 
(p < 0.001).  According to clinical practice, the use of invasive ventilation with endotracheal 
intubation in neonatal resuscitation is less and less used and replaced by noninvasive ventilation 
with the minimum effective pressure. [12] The type of delivery had no influence in 
pneumothorax occurrence, results that are consistent with others. [2, 27] Antenatal steroids use 
wasn´t associated with pneumothorax (p=0.976), data according with other studies. [28]  
The treatment of pneumothorax is not fully defined. In this study we had 80 
pneumothoraces, spontaneous in 46 (57.5%) neonates and iatrogenic in 34 (42.5%), but only 68 
(85%) received oxygen therapy, because pneumothoraces with very small size in chest x-ray 
solved spontaneously. As described in literature, other option for treatment is the expectant 
management for non hypertensive pneumothoraces in patients who are ventilated [3], and this 
approach was done  in 15 (18.8%) neonates with NCPAP and in 60 (75%) with CMV. The use 
of needle aspiration and chest tube are common options for the treatment. Thoracentesis was 
made in 10 (12.5%) pneumothoraces, however this treatment wasn´t effective in seven of them. 
So, thoracentesis only treated 3 (3.8%) non hypertensive pneumothoraces. It is known that, 
frequently, neonates treated with needle aspiration, can require subsequent chest-tube insertion. 
[29] In our study 57 (71.3%) neonates needed drains to be effectively treated.  
As described in Table 3, there was a statistical significant difference between cases and controls 
concerning respiratory pathology. When adjusted by multivariate analyses, RDS showed an 
OR=3.512 and TTN was OR=8.677, which means that they were positively related with 
pneumothorax, results comparable with other studies. [2,28] BPD was not statistically different 
between the two groups, as observed in other studies. [28,30] The risk of developing 
pneumothorax was also increased in newborns with other pathologies (IVH ≥3 grade, PDA, 
cystic PVL and hypotension), showing that pneumothoraces can occur in patients with more 
severe diseases. As we expected the administration of surfactant was more frequent in patients 
with pneumothoraces, probably due to the lung pathology associated with cases. In the present 
study, oxygen therapy, NCPAP and CMV were related with the development of pneumothorax. 
Linear regression analyses indicate that neonates who received IMV had a probability 3.8 times 
higher to develop pneumothorax and those who received oxygen therapy with a FiO2>0.4 had 
an increased risk of pneumothorax 5.6 times higher. Terzic et al. showed that infants who 
needed higher FiO2 were more likely to develop pneumothorax. [28] These results suggest that 
high pressures in NCPAP and CMV and a high FiO2 should be avoided. Congenital heart 
disease and diaphragmatic hernia were also statistical significant risk factors for pneumothorax, 
probably because of the pathophysiological disturbances of these pathologies or their surgical 
repair. Congenital diaphragmatic hernia is a risk factor for pulmonary hypoplasia once it 
occupies space, prevents lung expansion and causes a change in the thoracic cavity. [31] 
Neonates with pneumothorax had a prolonged stay in NICU, an average of 9.5 days. Possibly 
they had more associated pathology and needed treatment.  
We found that 30% of cases died comparing to 5.6% of controls (p<0.001). 
Hypotension, mechanical ventilation and thoracentesis associated with chest tube insertion were 
found to be predictors of mortality in newborns with pneumothoraces. These neonates had a bad 
prognosis since the beginning. However, in our study, pneumothorax was not identified as a 
predictor of mortality as had been shown by others [2,6] The good strategy and appropriate 
management used in the NICU was probably the explanation for this result. 
 The limitations of this study are to be a retrospective one, to have a small size sample 
and to represent a single center. 
 
Conclusion 
 
Pneumothorax is relatively frequent in the neonatal intensive care unit. Its risk factors 
(RDS, TTN, invasive mechanical ventilation and a FiO2>0.4 and predictors of mortality 
(hypotension, mechanical ventilation and thoracentesis followed by a chest tube insertion) 
should be well known, in order to prevent and treat this critical situation. 
Pneumothorax itself was not a predictor of mortality, probably due to the adequate and prompt 
management used in the NICU. 
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Table 1. Demographic and perinatal data 
 Total 
(n=240) 
Cases 
(n=80) 
Controls 
(n=160) 
P 
Gender, n (%) 
  Male  
  Female 
 
145 (60.4) 
95 (39.6) 
 
50 (62.5) 
30(37.5) 
 
95 (59.4) 
65(40.6) 
 
0.641* 
Gestational age (weeks), median 
(min-max)  
Gestational age (weeks), n (%) 
  < 37  
  <28  
37 (24-40) 
 
 
117 (48.8) 
29 (12.1) 
37 (24-40) 
 
 
39 (48.8) 
9 (11.3) 
37 (24-40) 
 
 
78 (48.8) 
20 (12.5) 
0.948¥ 
 
 
0.999* 
0.779* 
Birth weight (g), median (min-max) 
    
2612.5 
(360-4324) 
2588 
(360-4260) 
2642.5 
(450-4324) 
0.836¥ 
Parity, n (%) 
   Single 
   Multiple  
 
208 (86.7) 
32 (13.3) 
 
65 (81.3) 
15 (18.2) 
 
143 (89.4) 
17 (10.6) 
 
0.081* 
Antenatal steroids, n (%) 
   Full cycle   
72(30) 
53 (22.1) 
24 (30) 
18 (22.5) 
48 (30) 
35 (21.9) 
0.976* 
0.912*  
Type of Delivery, n (%) 
  Vaginal 
  C-section 
 
129 (53.8) 
111 (46.3) 
 
36 (45) 
44 (55) 
 
93 (58.1) 
67 (41.9) 
 
0.055* 
Apgar Score, n (%) 
  1st min <7 
  5th min <7 
 
76(31.7) 
27 (11.3) 
 
32(40) 
16 (20) 
 
44(27.5) 
11 (6.9) 
 
0.050* 
0.002* 
Resuscitation at birth, n (%) 
  Endotracheal Intubation    
64 (26.7) 
31(48.4) 
37 (46.3) 
22 (59.5) 
27 (16.9) 
9 (33.3) 
<0.001* 
0.039* 
* Chi-square test, ¥ Mann-Whitney U test.; p<0.05, statistical significance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Characterization and treatment of cases (n=80)  
A. Characterization of Pneumothoraces  
Spontaneous, n (%) 
   Primary 
   Secondary to lung disease 
46 (57.5) 
6 (13) 
40 (87) 
Iatrogenic, n (%) 
  Positive Pressure Ventilation 
  During surgery 
34 (42.5) 
32 (94.1) 
2 (5.9) 
Laterality, n (%) 
  Right 
  Left 
  Bilateral 
 
37 (46.3) 
35 (43.8) 
8 (10) 
 
B. Treatment of Pneumothoraces  
Oxygen therapy, n (%) 
  FIO2 after pneumothorax, median (min-max) 
  Days, median (min-max) 
68 (85) 
0.4 (0.21-1) 
4 (1-83) 
NCPAP, n (%)  
  Days, median (min-max) 
15 (18.8) 
9 (1-32) 
Mechanical Ventilation, n (%)  
  Days, median (min-max) 
60 (75) 
4 (1-48) 
Thoracentesis, n (%) 3 (3.8) 
Drain, n (%) 
  Days, median (min-max) 
57 (71.3) 
3(1-21) 
                     NCPAP: nasal continuous positive airway pressure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Clinical and management data 
 Total 
(n=240) 
Cases 
(n=80) 
Controls 
(n=160) 
P 
Pneumonia, n (%) 6 (7.5) 6 (7.5) 0 0.001** 
Meconium aspiration syndrome, n (%) 3 (1.3) 3 (3.8) 0 0.036** 
Respiratory distress syndrome, n (%) 35 (14,6)) 24 (30) 11 (6.9) <0.001* 
Severe pulmonary hypoplasia, n (%)  7 (2.9) 7 (8.8) 0 <0.001* 
Transient tachypnea of the newborn, n 
(%) 
16 (6.7) 10 (12.5) 6 (3.8) 0.010* 
Sepsis, n (%) 48 (20) 16 (20) 32 (20) 0.999* 
Bronchopulmonary dysplasia, n (%) 9 (3.8) 5 (6.3) 4 (2.5) 0.999** 
Intraventricular hemorrhage ≥3, n (%) 10 (4.2) 8 (10) 2 (1.3) 0.003** 
Retinopathy of prematurity ≥2, n (%) 6 (2.5) 2 (2.5) 4 (2.5) 0.999** 
Necrotizing enterocolitis ≥2, n (%) 10 (4.2) 3 (3.8) 7 (4.8) 0.999** 
Patent ductus arteriosus, n (%) 16 (6.7) 9 (11.3) 7 (4.4) 0.044* 
Cystic periventricular leukomalacia, n 
(%) 
6 (2.5) 6 (7.5) 0 0.001** 
Hypotension, n (%) 18 (7.5) 12 (15) 6 (3.8) 0.002* 
   Vasopressors, n (%) 16 (6.7) 11 (13.8) 5 (3.1) 0.002* 
Surfactant, n (%) 
  Doses, median (min-max)   
41 (17.1) 
1 (1-4) 
30 (37.5) 
1 (1-3) 
11 (6.9) 
2 (1-4) 
<0.001* 
<0.001¥ 
Oxygen therapy, n (%) 85 (35.4) 59 (73.8) 26 (16.3) <0.001* 
  Days of oxygen, median (min-max) 2 (1-75) 2 (1-25) 5 (1-75) <0.054¥ 
FiO2, median (min-max)   0.21 (0.21-1) 0.4 (0.21-1) 0.21 (0.21-1) <0.001¥ 
FiO2 > 0.4, n (%) 54 (22.5) 43 (53.8) 11 (6.9) <0.001* 
NCPAP, n (%) 
  Days, median (min-max)   
51 (21.3) 
2 (1-35) 
28 (35) 
1 (1-15) 
23 (14.4) 
3 (1-35) 
<0.001* 
0.006 ¥ 
Mechanical Ventilation, n (%)     
  Days, median (min-max)   
64 (26.7) 
1.5 (1-25) 
47 (58.8) 
2 (1-25) 
15 (9.4) 
1 (1-24) 
<0.001* 
0.141 ¥ 
PIP max, median (min-max)  24.5 (0-40) 25 (16-40) 22 (0-35) 0.161¥ 
PEEP max, median (min-max) 4 (0-7) 4 (2-6) 4 (0-7) 0.582¥ 
Thoracic congenital malformation, n 
(%)   
   Congenital cardiopathy 
   Diaphragmatic hernia 
   Esophageal atresia 
25 (10.4) 
11 (4.6) 
9 (3.8) 
5 (2.1) 
23 (28.8) 
11 (13.8) 
9 (11.3) 
3 (3.8) 
2 (1.3) 
0 
0 
2 (1.3) 
<0.001** 
<0.001** 
<0.001** 
0.337** 
Days of hospitalization, median (min-
max)  
5 (1-167) 9.5 (1-167) 4 (1-149) 
 
<0.001¥ 
Death, n (%) (3) 33 (13.8) 24 (30) 9 (5.6) <0.001* 
*Chi-square test; ** Fisher’s exact test; ¥ Mann-Whitney U test; p <0.05, statistical significance                     
NCPAP: nasal continuous positive airway pressure; PIP: Positive inspiratory pressure; PEEP: Positive end 
expiratory pressure. 
 
 
 
 
 
Table 4 – Risk factors of pneumothorax  
 OR* 95% CI p 
Respiratory distress syndrome  3.512 1.353-9.118 0.010 
Transient tachypnea of  the Newborn 8.677 2.752-27.354 <0.001 
FiO2> 0.4 5.614 1.828-17.238 0.003 
Mechanical ventilation 3.824 1.285-11.376 0.016 
OR- odds ratio, CI- confidence interval; p <0.05, statistical significance (Multivariate analysis) 
* Logistic regression;  
 
 
 
 
 
 
 
 
 
Table 5 – Predictors of mortality in newborns with pneumothoraces 
 OR* 95% CI p 
Pneumothorax 1.284 0.409-4.032 0.669 
Hypotension 6.165 1.702-22.327 0.006 
Thoracentesis  and chest 
tube insertion 
8.195 1.280-52.478 0.026 
Mechanical ventilation 29.551 8.257-105.765 <0.001 
OR- odds ratio, CI- confidence interval; p <0.05, statistical significance (Multivariate analysis) 
* Logistic regression  
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